- LOGIN
- MemberShip
- 2020-07-12 12:14
Dailypharm Korea will be available without login access until the end of December 2019.
Membership login access would be required from February 2020 to access more news and website services.
Membership login access would be required from February 2020 to access more news and website services.
- Company
- General hospitals to prescribe Jeil Pharmaceutical Lonsurf
- by Eo, Yun-Ho Jul 10, 2020 06:13am
- Major general hospitals in Korea are readying prescription of Jeil Pharmaceutical’s Lonsurf indicated to treat patients with colorectal cancer. According to pharmaceutical industry sources, Lonsurf (tipiracil/ trifluridine) has been passed by drug committees (DCs) at the Big Five&8212;Seoul National University Hospital, Samsung Medical
- Company
- 66 companies complain choline alfoscerate coverage reduction
- by Jul 10, 2020 06:13am
- A group of pharmaceutical companies filed a complaint against the government’s decision to reduce coverage on choline alfoscerate drugs. On July 8, 66 pharmaceutical companies with choline alfoscerate issued a joint statement about their complaint filed for Korea’s Health Insurance Review and Assessment Service (HIRA) to reassess the
- Company
- No obligation to notify the originals of the split strategy
- by Kim, Jin-Gu Jul 9, 2020 06:27am
- In the patent dispute of Galvus (Vildagliptin),” a diabetes treatment for DPP-4 inhibitors that was recently completed, a blind spot in the licensed patent linkage system occurred. Generic company did not “notify” the original company of the fact that they applied for an item license in the process of challenging patents with a so-called
- Company
- Amgen won the second trial of 'Enbrel' patent
- by Kim, Jin-Gu Jul 9, 2020 06:26am
- Samsung Bioepis' Enbrel biosimilar 'Eticovo' (Etanercept) is expected to postpone the US debut. A patent lawsuit was conducted that could affect the Eticovo's early launch strategy, but the US court sided with the original company. According to the pharmaceutical industry on the 6th, the U.S. Federal Court of Appeals earlier this month
- Company
- Phase III clinical trial plan for Rimatil has been submitted
- by Nho, Byung Chul Jul 8, 2020 09:14am
- Chong Kun Dang added a clinical pipeline for COVID-19 treatment following Nafabeltan. On the 18th of last month, Chong Kun Dang began the development of a COVID-19 treatment (clinical phase II) for its anticoagulant and acute pancreatitis treatment drug Nafabeltan (Nafamostat) on the 18th of last month. It is estimated that the mechanis
- Company
- “Liver cancer option expands, but needs further evidence”
- by Eo, Yun-Ho Jul 8, 2020 05:38am
- When a new drug development in a specific area is sluggish, there are two prominent reasons why; either the disease area has low marketability or the drug development itself for the disease is very difficult. In the latter case, a new drug gets an obvious spotlight when it is released to the market. Liver cancer (hepatocellular carcinoma
- Company
- Pfizer seeks for coverage on EGFR TKI to launch this year
- by Eo, Yun-Ho Jul 7, 2020 06:13am
- Pfizer Pharmaceutical Korea is quickly taking steps to join the competition in epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) market. According to the pharmaceutical industry sources, Pfizer is in process of listing EGFR TKI Vizimpro (dacomitinib) for healthcare reimbursement. Vizimpro took the pricing negoti
- Company
- GC Pharma has signed a contract to supply Pfizer's Rapamune
- by Jul 6, 2020 06:15am
- GC Pharma is launching a sale of Rapamune (Sirolimus), an immunosuppressive agent of Pfizer Korea. According to the distribution industry on the 3rd, GC Pharma signed a supply contract with Pfizer Korea for supply of Rapamune 0.5·1·2mg on the 19th of last month and began selling on the 1st of this month. Rapamune is an immunosuppressive
- Company
- Hanmi appealed patent lawsuit of Galvus
- by Kim, Jin-Gu Jul 6, 2020 06:14am
- As soon as the Patent Judge sidede with the original company in the patent dispute of Galvus (Vildagliptin), a DPP-4 inhibitor-based diabetes treatment agent, Hanmi immediately announced its appeal. An official from Hanmi said in a call with Dailypharm on the 2nd, "We will appeal immediately and receive a trial for the scope of the patent
- Company
- Hanmi loses first trial in patent dispute over Galvus
- by Kim, Jin-Gu Jul 6, 2020 06:14am
- Novartis won the patent dispute between Hanmi and Novartis over the DPP-4 inhibitor-based diabetes treatment agent Galvus (Vildagliptin). The Intellectual Property Trial And Appeal Board made a decision to dismiss the passive right scope verification trial requested by Hanmi on the 1st. Hanmi has filed a total of eight trials for Galvus p
